Unlocking the Potential of COL11A2 as a Drug Target and Biomarker

Target Name: COL11A2

NCBI ID: G1302

Unlocking the Potential of COL11A2 as a Drug Target and Biomarker

Introduction

COL11A2, also known as HKE5, is a protein that is expressed in various tissues of the human body, including the skin, lungs, heart, and kidneys. Its primary function is to regulate the production of collagen, a protein that is essential for the structure and integrity of many tissues in the body. Unfortunately, abnormal collagen production or degradation can contribute to a range of diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. As such, targeting COL11A2 as a drug target or biomarker has significant potential in the development of new therapies for these diseases.

The Structure and Function of COL11A2

COL11A2 is a single-chain transmembrane protein that contains 11 amino acid residues. It has a molecular weight of 11.9 kDa and a pre-steady-state nitrogen atom density of 13.8 kDa. The protein has a highly conserved cytoplasmic region, which includes a putative N-endoplasmic region (N-end), a transmembrane region (TM), and a C-terminal region (C-end). The N-end region is characterized by a putative glycophosphorylated serine (GPS) site and a putative acidic amino acid residue (A2), while the C-end region is conserved for the presence of a carboxylic acid residue (R16).

The primary function of COL11A2 is to regulate the production of collagen. Collagen is a complex protein that consists of a polymer chain composed of many subunit units. COL11A2 is involved in regulating the cross-linking degree and degradation of procollagen fibrils, thereby affecting the biological activity of collagen.

Mutations in COL11A2 can lead to changes in collagen structure, leading to the occurrence of a series of diseases, such as osteoporosis, vitiligo, dry skin and many cancers. Therefore, studying COL11A2 as a drug target or biomarker has important clinical significance.

COL11A2 potential as a drug target

Overexpression or deletion of COL11A2 has been confirmed in various cancers. For example, overexpression of COL11A2 is associated with multiple neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. At the same time, the loss of COL11A2 is associated with various cancers, such as lung cancer, breast cancer, and kidney cancer.

COL11A2's association with many cancers also makes it a potential candidate for a drug target. For example, COL11A2 has been used as a drug to treat skin cancer and kidney cancer, and has also shown promise in clinical trials to treat a variety of cancers.

The potential of COL11A2 as a biological specimen

In addition to being a drug target, COL11A2 can also be used as a biological specimen to study a variety of diseases. For example, the relationship between COL11A2 and skin aging and skin damage makes it a biomarker for studying skin aging and skin damage.

In addition, COL11A2 is also expressed in the respiratory system, cardiovascular system, urinary system and other tissues. Therefore, by detecting the expression level of COL11A2, the association of multiple diseases can be studied and provide clues for the development of new treatment strategies.

Therapeutic prospects of COL11A2

Although there are currently no drugs that specifically target COL11A2, many diseases related to collagen structure can be treated by modulating the activity of COL11A2. For example, the use of anticoagulant drugs, such as antiplatelet drugs, can reduce COL11A2-induced platelet aggregation, thus

Protein Name: Collagen Type XI Alpha 2 Chain

Functions: May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils

More Common Targets